The functions of mTOR in ischemic diseases
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Mammalian Target of Rapamycin (mTOR) is a serine/threonine kinase and that forms two multiprotein complexes known as the mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTOR regulates cell growth, proliferation and survival. mTORC1 is composed of the mTOR catalytic subunit and three associated proteins: raptor, mLST8/GβL and PRAS40. mTORC2 contains mTOR, rictor, mLST8/GβL, mSin1, and protor. Here, we discuss mTOR as a promising anti-ischemic agent. It is believed that mTORC2 lies down-stream of Akt and acts as a direct activator of Akt. The different functions of mTOR can be explained by the existence of two distinct mTOR complexes containing unique interacting proteins. The loss of TSC2, which is upstream of mTOR, activates S6K1, promotes cell growth and survival, activates mTOR kinase activities,inhibits mTORC1 and mTORC2 via mTOR inhibitors,and suppresses S6K1 and Akt. Although mTOR signaling pathways are often activated in human diseases, such as cancer,mTOR signaling pathways are deactivated in ischemic diseases. From Drosophila to humans, mTOR is necessary for Ser473 phosphorylation of Akt, and the regulation of Akt-mTOR signaling pathways may have a potential role in ischemic disease. This review evaluates the potential functions of mTOR in ischemic diseases. A novel mTOR-interacting protein deregulates over-expression in ischemic disease, representing a new mechanism for controlling mTOR signaling pathways and potential therapeutic strategies for ischemic diseases. [BMB reports 2011; 44(8): 506-511]
Abstract
Mammalian Target of Rapamycin (mTOR) is a serine/threonine kinase and that forms two multiprotein complexes known as the mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). mTOR regulates cell growth, proliferation and survival. mTORC1 is composed of the mTOR catalytic subunit and three associated proteins: raptor, mLST8/GβL and PRAS40. mTORC2 contains mTOR, rictor, mLST8/GβL, mSin1, and protor. Here, we discuss mTOR as a promising anti-ischemic agent. It is believed that mTORC2 lies down-stream of Akt and acts as a direct activator of Akt. The different functions of mTOR can be explained by the existence of two distinct mTOR complexes containing unique interacting proteins. The loss of TSC2, which is upstream of mTOR, activates S6K1, promotes cell growth and survival, activates mTOR kinase activities,inhibits mTORC1 and mTORC2 via mTOR inhibitors,and suppresses S6K1 and Akt. Although mTOR signaling pathways are often activated in human diseases, such as cancer,mTOR signaling pathways are deactivated in ischemic diseases. From Drosophila to humans, mTOR is necessary for Ser473 phosphorylation of Akt, and the regulation of Akt-mTOR signaling pathways may have a potential role in ischemic disease. This review evaluates the potential functions of mTOR in ischemic diseases. A novel mTOR-interacting protein deregulates over-expression in ischemic disease, representing a new mechanism for controlling mTOR signaling pathways and potential therapeutic strategies for ischemic diseases. [BMB reports 2011; 44(8): 506-511]
참고문헌 (59)
- Sarbassov, D. D, "Phosphorylation and regulation of Akt", PKB by the rictor-mTOR complex, 2005, pp.307, 1098~1101
- Wang, C. Y, "Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR", Sci. Signal, 2 (2009)
- Peterson, T. R, "DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival", Cell, 137, pp.873~886 (2009)
- Guertin, D. A, "Defining the Role of mTOR in Cancer", Cancer Cell, 12, pp.9~22 (2007)
- Bhaskar, P. T, "The two TORCs and Akt", Dev. Cell, 12, pp.487~502 (2007)
- Loewith, R, "Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control", Mol. Cell, 10, pp.457~468 (2002)
- Guertin, D. A, "Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1", Dev. Cell, 11, pp.859~871 (2006)
- Tokunaga, C, "mTOR integrates amino acid- and energy-sensing pathways", Biochem. Biophys. Res. Commun, 313, pp.443~446 (2004)
- Ma, X, "Molecular mechanisms of mTOR-mediated translational control", Nat. Rev. Mol. Cell Biol, 10, pp.307~318 (2009)
- Huang, J, "The TSC1-TSC2 complex: a molecular switchboard controlling cell growth", Biochem. J, 412, pp.179~190 (2008)
- Manning, B. D, "AKT", PKB signaling: navigating downstream, 2007, pp.129, 1261~1274
- Zhang, H, "PDGFRs are critical for PI3K", Akt activation and negatively regulated by mTOR, 2007, pp.117, 730~738
- Inoki, K, "TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling", Nat. Cell Biol, 4, pp.648~657 (2002)
- Kovacina, K. S, "Identification of a proline-rich Akt substrate as a 14-3-3 binding partner", J. Biol. Chem, 278, pp.10189~10194 (2003)
- Huang, B, "Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis", Acta. Pharmacol. Sin, 26, pp.1253~1258 (2005)
- Vander, H. E, "Insulin signalling to mTOR mediated by the Akt", PKB substrate PRAS40, 2007, pp.9, 316~323
- Sancak, Y, "PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase", Mol. Cell, 25, pp.903~915 (2007)
- Hanada, M, "Structure, regulation and function of PKB", AKT–a major therapeutic target, 2004, pp.1697, 3~16
- Jacinto, E, "SIN1", MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity, 2006, pp.127, 125~137
- Huang, J, "The TSC1-TSC2 complex is required for proper activation of mTOR complex 2", Mol. Cell Biol, 28, pp.4104~4115 (2008)
- Huang, J, "Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors", Cancer Res, 69, pp.6107~6114 (2009)
- Wullschleger, S, "TOR signaling in growth and metabolism", Cell, 124, pp.471~484 (2006)
- Shen, W. H, "Cardiac restricted overexpression of kinase-dead mammalian target of rapamycin (mTOR) mutant impairs the mTOR-mediated signaling and cardiac function", J. Biol. Chem, 283, pp.13842~13849 (2008)
- Tong, H, "Ischemic preconditioning activates phosphatidylinositol- 3-kinase upstream of protein kinase C", Circ. Res, 87, pp.309~315 (2000)
- Khan, S, "Rapamycin confers preconditioning- like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes", J. Mol. Cell Cardiol, 41, pp.256~264 (2006)
- Murphy, E, "Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury", Physiol. Rev, 88, pp.581~609 (2008)
- Balasubramanian, S, "mTOR in growth and protection of hypertrophying myocardium. Cardiovasc", Hematol. Agents Med. Chem, 7, pp.52~63 (2009)
- Jonassen, A. K, "Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cellsurvival signaling", Circ. Res, 89, pp.1191~1198 (2001)
- Oudit, G. Y, "Cardiac Regulation by Phosphoinositide 3-kinases and PTEN", Cardiovasc. Res, pp.250~260 (2009)
- Lyons, W. E, "Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory gangli", Proc. Natl. Acad. Sci. U.S.A, 91, pp.3191~3195 (1994)
- Steiner, J. P, "Neurotropic actions of nonimmuosuppressive analogues of immunosuppressive drugs FK506, rapamycin, and cyclosporine A", Nat. Med, 3, pp.421~428 (1997)
- Erlich, S, "Rapamycin is a neuroprotective treatment for traumatic brain injury", Neurobiol. Dis, 26, pp.86~93 (2007)
- Ruan, B, "Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities", Proc. Natl. Acad. Sci. U.S.A, 105, pp.33~38 (2008)
- Carloni, S, "Activation of autophagy and Akt", CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia, 2010, pp.6, 366~377
- Hein, S, "Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms", Circulation, 107, pp.984~991 (2003)
- Lekli, I, "Co-ordinated autophagy with resveratrol and γ-tocotrienol confers synergetic cardioprotection", J. Cell Mol. Med, 14, pp.2506~2518 (2010)
- Ma, H, "Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischemia", reperfusion injury: role of autophagy paradox and toxic aldehyde, 2011, pp.32, 1025~1038
- Zhang, Z, "Apelin protects against cardiomyocyte apoptosis induced by glucose deprivation", Chin. Med. J, 122, pp.2360~2365 (2009)
- Gurusamy, N, "Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway", Cardiovasc. Res, 86, pp.103~112 (2010)
- Trotman, L. C, "Identification of a tumour suppressor network opposing nuclear Akt function", Nature, 441, pp.523~527 (2006)
- Ayuso, M. I, "New hierarchical phosphorylation pathway of the translational repressor elF4E-binding protein 1 (4E-BP1) in ischemia-reperfusion stress", J. Biol. Chem, 285, pp.34355~34363 (2010)
- 고필옥, "Melatonin prevents ischemic brain injury through activation of the mTOR", p70S6 kinase signaling pathway, 2008, pp.444(0), 74~78[DOI]
- 고필옥, "Gingko biloba Extract (EGb 761) Prevents Cerebral Ischemia-Induced p70S6 Kinase and S6 Phosphorylation", AMERICAN JOURNAL OF CHINESE MEDICINE, 38(4), pp.727~734 (2010), WORLD SCIENTIFIC PUBL CO PTE LTD
- Shi, G. D, "PTEN deletion prevents ischemic brain injury by activating the mTOR signaling pathway", Biochem. Biophys. Res. Commun, 404, pp.941~945 (2011)
- Huang, C. Y, "Anti-apoptotic PI3K", Akt signaling by sodium, Lab Invest, pp.2011, 91[DOI]
- Zhang, Y, "Autophagy in ALDH2- elicited cardioprotection against ischemic heart disease: slayer or savior", Autophagy, 6, pp.1212~1213 (2010)
- Zhang, L, "Astragalus membranaceus extract promotes neovascularisation by VEGF pathway in rat model of ischemic injury", Pharmazie, 66, pp.144~150 (2011)
- Vigneron, F, "GSK-3βat the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways", Cardiovasc Res, 90, pp.49~56 (2011)
- Chong, Z. Z, "Mammalian target of rapamycin: hitting the bull’s-eye for neurological disorders", Oxid. Med. Cell. Longev, 3, pp.374~391 (2010)
- Shang, J, "Antiapoptotic and antiautophagic effects of glial cell line-derived neurotrophic factor and hepatocyte growth factor after transient middle cerebral artery occlusion in rats", J. Neurosci Res, 88, pp.2197~2206 (2010)
- Vézina, C, "Rapamycin (AY-22,989), a new antifungal antibiotic", J. Antibiot, 28, pp.721~726 (1975)
- Dumont, F. J, "Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin", J. Immunol, 144, pp.251~258 (1990)
- Chresta, C. M, "AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity", Cancer Res, 70, pp.288~298 (2010)
- Dees, E. C, "A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors", Clin. Cancer Res, 11, pp.664~671 (2005)
- Granville, C. A, "Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase", Akt, Clin Cancer Res, pp.2006, 12[DOI]
- Kondapaka, S. B, "Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation", Mol. Cancer Ther, 2, pp.1093~1103 (2003)
- Ma, W. W, "Temsirolimus", Drugs Today, 43, pp.659~669 (2007)
- O’Donnell, A, "A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours", Proc. Am. Soc. Clin. Oncol, 22, pp.803~ (2003)
- Sausville, E. A, "Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractoryneoplasms", J. Clin. Oncol, 19, pp.2319~2333 (2001)